FDA Approves Genentech’s Enspryng, a First — in — Class IL — 6R Inhibitor, as the First and Only At — Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)
For best results when printing this announcement, please click on link below: FDA Approves Genentech’s Enspryng, a First-in-Class IL-6R Inhibitor, as the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED) FDA approval based on Phase III SatraGO-1 and -2 studies, with SatraGO-2 demonstrat